You just read:

BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

News provided by

BioMarin Pharmaceutical Inc.

Dec 19, 2017, 15:05 ET